Compare Aurobindo Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs GSK PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA GSK PHARMA AUROBINDO PHARMA/
GSK PHARMA
 
P/E (TTM) x 18.4 50.7 36.2% View Chart
P/BV x 4.0 11.4 34.7% View Chart
Dividend Yield % 0.3 1.4 19.2%  

Financials

 AUROBINDO PHARMA   GSK PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
GSK PHARMA
Mar-19
AUROBINDO PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs8303,595 23.1%   
Low Rs5271,253 42.1%   
Sales per share (Unadj.) Rs333.9184.7 180.8%  
Earnings per share (Unadj.) Rs40.426.3 153.5%  
Cash flow per share (Unadj.) Rs51.829.2 177.5%  
Dividends per share (Unadj.) Rs2.5020.00 12.5%  
Dividend yield (eoy) %0.40.8 44.7%  
Book value per share (Unadj.) Rs237.1126.3 187.7%  
Shares outstanding (eoy) m585.91169.40 345.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.013.1 15.5%   
Avg P/E ratio x16.892.2 18.2%  
P/CF ratio (eoy) x13.183.1 15.8%  
Price / Book Value ratio x2.919.2 14.9%  
Dividend payout %6.276.1 8.1%   
Avg Mkt Cap Rs m397,569410,626 96.8%   
No. of employees `00017.95.0 360.0%   
Total wages/salary Rs m25,8495,372 481.2%   
Avg. sales/employee Rs Th10,956.96,306.7 173.7%   
Avg. wages/employee Rs Th1,447.71,083.1 133.7%   
Avg. net profit/employee Rs Th1,324.3898.0 147.5%   
INCOME DATA
Net Sales Rs m195,63631,281 625.4%  
Other income Rs m1,5531,023 151.8%   
Total revenues Rs m197,18932,304 610.4%   
Gross profit Rs m39,5196,009 657.7%  
Depreciation Rs m6,680486 1,374.4%   
Interest Rs m2,6266 43,766.7%   
Profit before tax Rs m31,7676,540 485.7%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-881287 -306.8%   
Tax Rs m7,2692,373 306.3%   
Profit after tax Rs m23,6454,454 530.9%  
Gross profit margin %20.219.2 105.2%  
Effective tax rate %22.936.3 63.1%   
Net profit margin %12.114.2 84.9%  
BALANCE SHEET DATA
Current assets Rs m153,64520,061 765.9%   
Current liabilities Rs m120,42914,543 828.1%   
Net working cap to sales %17.017.6 96.2%  
Current ratio x1.31.4 92.5%  
Inventory Days Days13557 238.1%  
Debtors Days Days6414 453.0%  
Net fixed assets Rs m103,90914,343 724.5%   
Share capital Rs m5861,694 34.6%   
"Free" reserves Rs m138,32219,704 702.0%   
Net worth Rs m138,90821,398 649.2%   
Long term debt Rs m1,8002 89,975.0%   
Total assets Rs m264,54439,113 676.4%  
Interest coverage x13.11,091.0 1.2%   
Debt to equity ratio x00 13,860.4%  
Sales to assets ratio x0.70.8 92.5%   
Return on assets %9.911.4 87.1%  
Return on equity %17.020.8 81.8%  
Return on capital %23.831.9 74.7%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,316534 18,224.0%   
Fx outflow Rs m40,5897,091 572.4%   
Net fx Rs m56,727-6,557 -865.1%   
CASH FLOW
From Operations Rs m16,2203,994 406.1%  
From Investments Rs m-28,768-1,433 2,007.0%  
From Financial Activity Rs m19,191-3,584 -535.5%  
Net Cashflow Rs m6,656-1,023 -650.5%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 8.0 10.2 77.9%  
FIIs % 27.7 23.8 116.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 15.4 66.2%  
Shareholders   69,601 102,036 68.2%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DR. DATSONS LABS  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT PHARMOVA   DIVIS LABORATORIES  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Apr 9, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS